Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...

A Lilly investigational obesity pill largely helped patients maintain their weight loss after they switched from injectable ...

In the ATTAIN-MAINTAIN study of its orforglipron candidate, switching to the drug after 72 months of injectable treatment ...

Wegovy maker Novo Nordisk filed for U.S. FDA approval of CagriSema, a once-weekly shot that combines two compounds to treat ...

Eli Lilly’s orforglipron pill helps maintain weight loss after Zepbound or Wegovy injections, with FDA review underway. Learn ...

A selective androgen receptor modulator combined with a GLP-1 may induce weight loss for older adults with obesity while ...

Eli Lilly has shown patients maintained most of their weight loss after switching from injectable GLP-1s to its oral drug ...

Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the ATTAIN-MAINTAIN trial. The Phase 3 study ...

Eli Lilly & Co. reported positive topline results from a trial of its oral weight-management drug orforglipron.

Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for ...

Eli Lilly (LLY) stock is in focus as the company posts late-stage trial data to indicate that its obesity pill orforglipron ...

Eli Lilly's oral pill, orforglipron, helped maintain weight loss in patients switching from injectable versions of GLP-1 ...